[{"_1":2,"_3":-5,"_4":-5},"loaderData",{"_5":6,"_7":8},"actionData","errors","root",{"_107":108},"en-item",{"_9":10,"_10":11},"kind","item",{"_12":13,"_14":15,"_16":17,"_18":19,"_20":21,"_22":23,"_24":25,"_26":27,"_28":29,"_30":31,"_32":31,"_33":34,"_35":36,"_37":38,"_39":40,"_41":42,"_43":44,"_45":46,"_47":-5,"_48":49,"_50":-5,"_51":-5,"_52":53,"_54":55,"_56":57,"_58":42,"_59":42,"_60":61,"_62":42,"_63":64},"id","cdg0xzxansv2wzciziyqeijsz","revision",2,"title","Ultragenyx Pharmaceutical Inc. 以2.03亿美元出售PRV","originalTitle","8-K - Ultragenyx Pharmaceutical Inc. (0001515673) (Filer)","summary","Ultragenyx Pharmaceutical Inc. 于2026年10月8日与买方签署资产购买协议，出售其获得的罕见儿科疾病优先审查凭证（PRV），交易金额为2.03亿美元现金。","reason","Ultragenyx Pharmaceutical Inc. 将以2.03亿美元出售罕见儿科疾病优先审查凭证，交易尚需满足常规交割条件。","source",{"_12":98,"_99":100,"_9":101,"_102":42,"_103":104,"_105":106},"links",{"_95":96,"_84":97},"publishedAt","2026-10-14T13:00:14.000Z","discoveredAt","2026-10-14T13:09:34.843Z","timelineAt","category","ai-products","tags",[89,90,91,92,93,94],"stockSymbols",[88],"score",66,"selected",true,"channel","news","story",{"_74":75,"_16":76},"x","readingMode","full","author","language","body",{"_64":83,"_84":-5,"_85":86,"_87":42},"outline",[78],"relatedStories",[77],"indexable","markdownAvailable","group",{"_65":66,"_45":67,"_68":69,"_70":71,"_72":73},"hasTranslation","bodyLanguage","zh","factId","faviVcs2kZds",{"_74":75,"_16":76},"reportCount",3,"additionalSourceCount",1,"developmentCount",0,"publicId","dd63ccfb-064f-4826-9872-b654adddac38","Ultragenyx出售罕见病PRV获2.03亿美元",{"_74":75,"_16":76},{"_12":79,"_80":81,"_82":15},"sec-1","text","表格 8-K","level","

美国
证券交易委员会
华盛顿特区 20549

表格 8-K

当前报告

根据1934年证券交易法第13条或第15(d)条

\n \n \n \n \n \n

报告日期（最早事件报告日期）： 2026年10月08日

Ultragenyx Pharmaceutical Inc.

(注册人根据其章程指定的名称)

\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n

\n	\n	\n	\n	\n
特拉华州	001-36276	27-2546083
(注册州或其它司法管辖区 )	(委员会文件编号)	(美国国税局雇主识别号码)

60 Leveroni Court
Novato, 加利福尼亚州		94949
(主要执行办公室地址)		(邮政编码)

\n \n \n \n \n \n

注册人的电话号码，包括区号： 415 483-8800

\n \n \n \n \n \n

(如果自上次报告以来名称或地址有所更改，请在此处注明)

如果本8-K表格的提交旨在同时满足注册人根据以下任何规定下的提交义务，请在下面的适当方框中打勾：

☐根据证券法第425条规则的书面沟通（17 CFR 230.425）

☐根据交易所法第14a-12条规则的征求材料（17 CFR 240.14a-12）

☐根据交易所法第14d-2(b)条规则的开始前沟通（17 CFR 240.14d-2(b)）

☐根据交易所法第13e-4(c)条规则的开始前沟通（17 CFR 240.13e-4(c)）

根据证券交易法第12(b)条注册的证券：

\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n

\n	\n	\n	\n	\n
每类证券的名称		交易符号		每种证券注册的交易所名称
普通股，面值0.001美元		RARE		纳斯达克全球精选市场

通过勾选方框表明注册人是否为根据1933年证券法第405条（§ 230.405）或1934年证券交易法第12b-2条（§ 240.12b-2）定义的新兴成长公司。

新兴成长公司 ☐

如果为新兴成长公司，请通过勾选方框表明注册人是否已选择不使用根据交易所法第13(a)条提供的任何新修订的财务会计标准的延长过渡期。☐

\n \n \n \n \n \n \n

\n	\n
项目 1.01	进入重大最终协议。

2026年10月8日，Ultragenyx Pharmaceutical Inc.（“公司”）签订了一份资产购买协议（“PRV资产购买协议”），根据该协议，公司同意将一份罕见儿科疾病优先审查凭证（“PRV”）出售给买方。公司于2026年9月17日，在FAYUVITM（rebisufligene etisparvovec-hopf），也称为UX111，获得美国食品药品监督管理局（“FDA”）批准用于治疗患有黏多糖贮积症III型A型（MPS IIIA，桑菲利波综合征A型）的儿科患者后，获得了该PRV。TM根据PRV资产购买协议，买方同意在交易完成时以现金支付2.03亿美元给公司。

PRV资产购买协议包含常规的陈述、保证、承诺和赔偿条款，但受某些限制的约束。该交易仍需满足常规的交割条件，包括根据1976年哈特-斯科特-罗迪诺反垄断改进法案适用的等待期届满或终止。

前述PRV资产购买协议的描述并非完整，其全部内容以PRV资产购买协议的全文为准，该协议副本将提交至公司2026年12月31日止年度的10-K表年度报告中。

签名

根据1934年证券交易法的要求，注册人已 duly 促使本报告由下文签署人 duly 授权代表公司签署。

\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n

\n	\n	\n	\n
			Ultragenyx Pharmaceutical, Inc.

日期：	2026年10月14日	签字：	/s/ Howard Horn
			Howard Horn 执行副总裁，首席财务官，企业战略

","original","zhKind","translation","complete","RARE","公司与财报","行业与主题","政策与监管","其他","宏观与美联储","市场观察","aihot","/items/cdg0xzxansv2wzciziyqeijsz","https://www.sec.gov/Archives/edgar/data/1515673/000119312526421079/0001193125-26-421079-index.htm","rss-sec-xbrl","name","SEC · EDGAR 财务披露","rss","firstParty","iconUrl","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar&exp=1792195200&sig=4eab1165515e57e2","iconSrcSet","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-48&exp=1792195200&sig=df95c58c297800b1 48w, /api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-96&exp=1792195200&sig=2a4278e6e5e85947 96w","changelogVersion","2026-10-01T08:00"]